

**Saving Hearts and Lives in Advanced Prostate Cancer: Choosing Between ADT
Agonists and Antagonists: Clinical Case #3**

References

- Abidov A, Chehab O. Cardiovascular risk assessment models: have we found the perfect solution yet? *J Nucl Cardiol*. 2020;27(6):2375-2385. doi:10.1007/s12350-019-01642-x
- Accordino MK, Hershman DL. Disparities and challenges in adherence to oral antineoplastic agents. *Am Soc Clin Oncol Educ Book*. 2013;(33):271-276. doi:10.1200/EdBook_AM.2013.33.271
- American College of Cardiology. ASCVD risk estimator plus. Accessed November 1, 2021. <https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate>
- Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. *Eur Urol*. 2015;68(3):386-396. doi:10.1016/j.eururo.2014.11.039
- Bolton EM, Lynch T. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review. *BJU Int*. 2018;122(3):371-383. doi:10.1111/bju.14168
- Borrelli E, McGladrigan CG. PCN80 estimating the difference in annual out-of-pocket costs for relugolix and leuprolide for medicare patients with metastatic prostate cancer. *Value in Health*. 2021;24:S34. doi:10.1016/j.jval.2021.04.172
- Burruss R, Arikian V, Oleru K, Traurig T, Stranz M, Lindhorst J. PCN208 association of quality of life with oncology medication adherence in cancer patients on the service of a specialty pharmacy. *Value in Health*. 2021;24:S58. doi:10.1016/j.jval.2021.04.299
- Centers for Disease Control and Prevention. Heart disease facts. Updated September 27, 2021. Accessed November 1, 2021. <https://www.cdc.gov/heartdisease/facts.htm>
- Cohen Castel O, Dagan E, Keinan-Boker L, Low M, Shadmi E. Patients' perceived continuity of care and adherence to oral anticancer therapy: a prospective cohort mediation study. *J Gen Intern Med*. 2021;36(6):1525-1532. doi:10.1007/s11606-021-06704-w
- Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. *BMJ Open*. 2018;8(1):e016982. doi:10.1136/bmjopen-2017-016982

Dean LT, George M, Lee KT, Ashing K. Why individual-level interventions are not enough: systems-level determinants of oral anticancer medication adherence. *Cancer*. 2020;126(16):3606-3612. doi:10.1002/cncr.32946

Dowling M, Hunter A, Biesty L, et al. Driving and disabling factors of noncurative oral chemotherapy adherence: a qualitative evidence synthesis. *Oncol Nurs Forum*. 2019;46(1):16-28. doi:10.1188/19.ONF.16-28

Hu JR, Duncan MS, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. *Arterioscler Thromb Vasc Biol*. 2020;40(3):e55-e64. doi:10.1161/ATVBAHA.119.313046

Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. *BJU Int*. 2008;102(11):1531-1538. doi:10.1111/j.1464-410X.2008.08183.x

LUPRON DEPOT (leuprolide) [prescribing information]. AbbVie Inc. Approved 1989. Revised March 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020517s042,019732s044lbl.pdf

Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. *BMC Cancer*. 2016;16(1):180. doi:10.1186/s12885-016-2221-5

McGowan M. Women heart: enhancing medication & treatment adherence for women with heart disease. National Forum for Heart Disease & Stroke Prevention. Updated October 19. Accessed January 26, 2022. <https://www.nationalforum.org/wp-content/uploads/2017/12/McGowan-WomenHeart-Enhancing-Medication-and-Treatment-Adherence-for-Women-with-Heart-Disease-10.19.16.pdf>

Pinthus JH, Shayegan B, Klotz L, et al. The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation. *J Clin Oncol*. 2020;38(6_suppl):364-364.

Sabaté E. *Adherence to Long-term Therapies: Evidence for Action*. World Health Organization; 2003. Accessed October 1, 2021. <https://apps.who.int/iris/handle/10665/42682>

Sari Motlagh R, Abufaraj M, Mori K, et al. The efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: a network meta-analysis of randomized trials. *Eur Urol Oncol*. 2021. doi:10.1016/j.euo.2021.07.002

Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. *N Engl J Med*. 2020;382(23):2187-2196. doi:10.1056/NEJMoa2004325

TRELSTAR® (triptorelin) [prescribing information]. Allergan. Approved 2000. Revised December 2018.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020715s040,021288s035,022427s015lbl.pdf

Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. *Circulation*. 2021;143(8):e254-e743. doi:10.1161/CIR.0000000000000950

Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364(9438):937-952. doi:10.1016/S0140-6736(04)17018-9

Weinman J, Ali I, Hodgkinson A, Canfield M, Jackson C. Pilot Testing Of A Brief Pre-Consultation Screener For Improving The Identification And Discussion Of Medication Adherence In Routine Consultations. *Patient Prefer Adherence*. 2019;13:1895-1898. doi:10.2147/PPA.S219860

Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. *PLoS One*. 2014;9(9):e107516. doi:10.1371/journal.pone.0107516

ZOLADEX® (goserelin) [prescribing information]. AstraZeneca. Approved 1989. Revised December 2020.
https://documents.tercera.com/zoladex-us/3.6mg_MagnumPI.pdf

ZOLADEX® (goserelin) [prescribing information]. AstraZeneca. Approved 1996. Revised December 2020.
https://documents.tercera.com/zoladex-us/10.8mg_MagnumPI.pdf

Glossary

ADT, androgen deprivation therapy
AE, adverse event
AIDS, acquired immunodeficiency syndrome
ALT, alanine aminotransferase
ASCVD, atherosclerotic cardiovascular disease
AST, aspartate aminotransferase
BMI, body mass index
BMQ, Beliefs about Medicines Questionnaire
BP, blood pressure
CV, cardiovascular
CVD, cardiovascular disease
EMR, electronic medical record
FSH, follicle-stimulating hormone
GI, gastrointestinal
GnRH, gonadotropin hormone-releasing hormone
HDL, high-density lipoprotein
HIV, human immunodeficiency virus
HR, hazard ratio
HTN, hypertension
LDL, low-density lipoprotein
MACE, major adverse cardiovascular event
MMAS4, Morisky Medication Adherence Scale, four items
MMWFU, Making Medicines Work For You Scale
NA, not applicable
nmHSPC, nonmetastatic hormone-sensitive prostate cancer
PCa, prostate cancer
PSADT, prostate-specific antigen doubling time
PET, positron emission tomography
PRO, patient-reported outcome
PSMA, prostate-specific membrane antigen
QOL, quality of life
QT, Q wave – T wave
RR, relative risk
UTI, urinary tract infection
w/, with